PE20070405A1 - Compuestos derivados de xantina como agonistas del receptor de acido nicotinico hm74a - Google Patents
Compuestos derivados de xantina como agonistas del receptor de acido nicotinico hm74aInfo
- Publication number
- PE20070405A1 PE20070405A1 PE2006000963A PE2006000963A PE20070405A1 PE 20070405 A1 PE20070405 A1 PE 20070405A1 PE 2006000963 A PE2006000963 A PE 2006000963A PE 2006000963 A PE2006000963 A PE 2006000963A PE 20070405 A1 PE20070405 A1 PE 20070405A1
- Authority
- PE
- Peru
- Prior art keywords
- chloro
- xanthine
- agonists
- nicotinic acid
- pentil
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 101000843809 Homo sapiens Hydroxycarboxylic acid receptor 2 Proteins 0.000 title abstract 2
- 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- -1 2,4,6-TRIFLUOROPHENYL Chemical class 0.000 abstract 3
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 229940075420 xanthine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0516464A GB0516464D0 (en) | 2005-08-10 | 2005-08-10 | Novel compounds |
| GB0607736A GB0607736D0 (en) | 2006-04-19 | 2006-04-19 | Novel compounds |
| GB0614569A GB0614569D0 (en) | 2006-07-21 | 2006-07-21 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070405A1 true PE20070405A1 (es) | 2007-05-06 |
Family
ID=37189397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000963A PE20070405A1 (es) | 2005-08-10 | 2006-08-08 | Compuestos derivados de xantina como agonistas del receptor de acido nicotinico hm74a |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20100179128A1 (enExample) |
| EP (3) | EP1912992A1 (enExample) |
| JP (2) | JP5112316B2 (enExample) |
| KR (2) | KR20080034993A (enExample) |
| AR (1) | AR055369A1 (enExample) |
| AT (1) | ATE487719T1 (enExample) |
| AU (2) | AU2006278216A1 (enExample) |
| BR (2) | BRPI0615145A2 (enExample) |
| CA (2) | CA2626723A1 (enExample) |
| CR (2) | CR9749A (enExample) |
| CY (1) | CY1111757T1 (enExample) |
| DE (1) | DE602006018151D1 (enExample) |
| DK (1) | DK1912991T3 (enExample) |
| EA (2) | EA014556B1 (enExample) |
| ES (1) | ES2401128T3 (enExample) |
| HR (1) | HRP20100725T1 (enExample) |
| IL (2) | IL189083A0 (enExample) |
| MA (2) | MA29692B1 (enExample) |
| MX (2) | MX2008001931A (enExample) |
| MY (1) | MY142067A (enExample) |
| NO (2) | NO20081211L (enExample) |
| NZ (1) | NZ565494A (enExample) |
| PE (1) | PE20070405A1 (enExample) |
| PL (1) | PL1912991T3 (enExample) |
| PT (1) | PT1912991E (enExample) |
| SI (1) | SI1912991T1 (enExample) |
| TW (1) | TW200800217A (enExample) |
| WO (2) | WO2007017262A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7495005B2 (en) * | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
| CN101863888B (zh) * | 2004-02-14 | 2012-07-18 | 葛兰素史密斯克莱有限责任公司 | 具有hm74a受体活性的药物 |
| DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
| EA014556B1 (ru) * | 2005-08-10 | 2010-12-30 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Производные ксантина в качестве селективных агонистов hm74a |
| ATE486874T1 (de) | 2006-06-23 | 2010-11-15 | Incyte Corp | Purinonderivate als hm74a-agonisten |
| AU2007260851B2 (en) | 2006-06-23 | 2013-01-17 | Incyte Corporation | Purinone derivatives as HM74a agonists |
| MX2009001043A (es) | 2006-08-08 | 2009-02-06 | Sanofi Aventis | Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso. |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007063671A1 (de) | 2007-11-13 | 2009-06-25 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| AU2009324811B2 (en) | 2008-12-08 | 2013-01-24 | Glaxosmithkline Llc | Novel compounds |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| MX2012001729A (es) | 2009-08-26 | 2012-06-13 | Sanofi Sa | Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo. |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| KR101799429B1 (ko) * | 2010-05-03 | 2017-11-21 | 에스케이바이오팜 주식회사 | 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물 |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| BR112013003439A2 (pt) * | 2010-08-16 | 2019-09-24 | Boehringer Ingelheim Int | "inibidores de oxadiazol de produção de leucotrieno" |
| EP2619196B1 (en) * | 2010-09-23 | 2015-09-16 | Boehringer Ingelheim International GmbH | Oxadiazole inhibitors of leukotriene production |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CA2868240A1 (en) * | 2012-05-30 | 2013-12-05 | F. Hoffmann-La Roche Ag | Triazolo compounds as pde10 inhibitors |
| PE20151779A1 (es) * | 2013-03-15 | 2015-11-20 | Hydra Biosciences Inc | Xantinas sustituidas y metodos de uso de las mismas |
| EP2994141A4 (en) | 2013-05-10 | 2016-11-23 | Nimbus Apollo Inc | ACC-HEMMER AND USES THEREOF |
| CN105358152A (zh) * | 2013-05-10 | 2016-02-24 | 尼普斯阿波罗有限公司 | Acc抑制剂和其用途 |
| HK1221661A1 (zh) | 2013-05-10 | 2017-06-09 | Gilead Apollo, Llc | Acc抑制剂和其用途 |
| EA030958B1 (ru) | 2013-05-10 | 2018-10-31 | Джилид Аполло, Ллс | Ингибиторы акк и их применение |
| CN105646492B (zh) * | 2014-11-14 | 2019-04-09 | 中国医学科学院药物研究所 | 含五元芳杂环的取代黄嘌呤类化合物及其制备方法和用途 |
| DE102017000359A1 (de) | 2016-08-26 | 2018-03-01 | Bihl+Wiedemann Gmbh | Diagnose-Repeater für AS-Interface Netze |
| JP7178357B2 (ja) * | 2017-03-07 | 2022-11-25 | エフ．ホフマン－ラ ロシュ アーゲー | オキサジアゾール一過性受容器電位チャネル阻害剤 |
| CN112724141A (zh) * | 2021-01-21 | 2021-04-30 | 南京艾美斐生物医药科技有限公司 | 一种gpr109a蛋白受体抑制剂及其制备和应用 |
| MX2024009581A (es) * | 2022-02-03 | 2024-08-13 | De Shaw Res Llc | Compuestos de uracilo n3-sustituidos como inhibidores de trpa1. |
| TW202440084A (zh) * | 2023-01-30 | 2024-10-16 | 美商Ｄ Ｅ 蕭爾研究有限公司 | 作為trpa1抑制劑之雙環醯亞胺化合物 |
| AR133217A1 (es) * | 2023-07-10 | 2025-09-10 | De Shaw Res Llc | Inhibidores de trpa1 bicíclicos y monocíclicos |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2797220A (en) | 1954-12-02 | 1957-06-25 | Univ Michigan | Substituted paraxanthines |
| GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| NZ240644A (en) | 1990-11-21 | 1994-08-26 | Smithkline Beecham Corp | Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf) |
| AU3725893A (en) | 1992-02-21 | 1993-09-13 | Smithkline Beecham Corporation | TNF inhibitors |
| ATE230990T1 (de) | 1992-03-04 | 2003-02-15 | Cell Therapeutics Inc | Enantiomere hydroxylierte xanthinverbindungen |
| US5473070A (en) | 1992-11-16 | 1995-12-05 | Cell Therapeutics, Inc. | Substituted long chain alcohol xanthine compounds |
| US5780476A (en) | 1992-11-16 | 1998-07-14 | Cell Therapeutics, Inc. | Hydroxyl-containing xanthine compounds |
| US6469017B1 (en) | 1998-01-16 | 2002-10-22 | Cell Therapeutics, Inc. | Method of inhibiting interleukin-12 signaling |
| US6693105B1 (en) | 1992-11-16 | 2004-02-17 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
| IL109161A0 (en) | 1993-03-31 | 1994-06-24 | Cell Therapeutics Inc | Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same |
| US5670506A (en) | 1993-04-05 | 1997-09-23 | Cell Therapeutics, Inc. | Halogen, isothiocyanate or azide substituted xanthines |
| WO1994024133A1 (en) | 1993-04-09 | 1994-10-27 | Cell Therapeutics, Inc. | Ring-substituted cell signaling inhibitors |
| WO1995020589A1 (en) | 1994-01-28 | 1995-08-03 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
| CA2183562A1 (en) | 1994-02-18 | 1995-08-24 | J. Peter Klein | Intracellular signalling mediators |
| US6878715B1 (en) | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
| US6780865B1 (en) | 1994-02-18 | 2004-08-24 | Cell Therapeutics, Inc. | Compounds having selective hydrolytic potentials |
| US6103730A (en) | 1994-03-24 | 2000-08-15 | Cell Therapeutics, Inc. | Amine substituted compounds |
| US5807861A (en) | 1994-03-24 | 1998-09-15 | Cell Therapeutics, Inc. | Amine substituted xanthinyl compounds |
| US6323201B1 (en) * | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
| AR015966A1 (es) | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
| EP1171442B1 (en) | 1999-04-09 | 2005-12-07 | Cell Therapeutics, Inc. | Xanthine derivatives and analogs as cell signalling inhibitors |
| US20030207901A1 (en) | 1999-07-27 | 2003-11-06 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
| US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
| US6586429B2 (en) * | 2000-11-29 | 2003-07-01 | Cell Therapeutics, Inc. | Tricyclic fused xanthine compounds and their uses |
| HU230382B1 (hu) | 2001-02-24 | 2016-03-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként |
| AU2002242910A1 (en) | 2001-04-11 | 2002-10-28 | Glaxo Group Limited | Medicaments which are modulators of hm74 and/or hm74a activity |
| ATE388951T1 (de) * | 2001-07-03 | 2008-03-15 | Novo Nordisk As | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes |
| DE60304911D1 (de) | 2002-02-25 | 2006-06-08 | Eisai Co Ltd | Xanthin-Derivate als DPP-IV-Inhibitoren |
| US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| CN1227492C (zh) * | 2003-03-11 | 2005-11-16 | 张跃 | 一种吸收式空调主体 |
| GB0319124D0 (en) * | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
| CN101863888B (zh) * | 2004-02-14 | 2012-07-18 | 葛兰素史密斯克莱有限责任公司 | 具有hm74a受体活性的药物 |
| KR20070070231A (ko) * | 2004-10-22 | 2007-07-03 | 스미스클라인 비참 코포레이션 | Ｈｍ７４ａ 수용체 활성을 가지는 크산틴 유도체 |
| WO2006045564A1 (en) * | 2004-10-22 | 2006-05-04 | Smithkline Beecham Corporation | Xanthine derivatives with hm74a receptor activity |
| US20090209561A1 (en) * | 2004-10-22 | 2009-08-20 | Richard Jonathan Daniel Hatley | Xanthine Derivatives with HM74A Receptor Activity |
| JP2008530074A (ja) | 2005-02-14 | 2008-08-07 | スミスクライン・ビーチャム・コーポレイション | Ｈｍ７４ａ受容体アゴニストとしてのアントラニル酸誘導体 |
| GB0516462D0 (en) * | 2005-08-10 | 2005-09-14 | Smithkline Beecham Corp | Novel compounds |
| EA014556B1 (ru) * | 2005-08-10 | 2010-12-30 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Производные ксантина в качестве селективных агонистов hm74a |
| DE102008009758A1 (de) * | 2008-02-18 | 2009-08-20 | Beiersdorf Ag | Verwendung von 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on zur verbesserten Hautkonturierung bzw. gegen Cellulite |
| AU2009324811B2 (en) | 2008-12-08 | 2013-01-24 | Glaxosmithkline Llc | Novel compounds |
-
2006
- 2006-08-08 EA EA200800555A patent/EA014556B1/ru not_active IP Right Cessation
- 2006-08-08 JP JP2008525474A patent/JP5112316B2/ja not_active Expired - Fee Related
- 2006-08-08 KR KR1020087005717A patent/KR20080034993A/ko not_active Ceased
- 2006-08-08 EP EP06776699A patent/EP1912992A1/en not_active Withdrawn
- 2006-08-08 BR BRPI0615145-0A patent/BRPI0615145A2/pt not_active Application Discontinuation
- 2006-08-08 PT PT06763016T patent/PT1912991E/pt unknown
- 2006-08-08 MX MX2008001931A patent/MX2008001931A/es active IP Right Grant
- 2006-08-08 JP JP2008525475A patent/JP2009504592A/ja not_active Withdrawn
- 2006-08-08 MY MYPI20063833A patent/MY142067A/en unknown
- 2006-08-08 HR HR20100725T patent/HRP20100725T1/hr unknown
- 2006-08-08 AU AU2006278216A patent/AU2006278216A1/en not_active Abandoned
- 2006-08-08 KR KR1020087005724A patent/KR20080038396A/ko not_active Withdrawn
- 2006-08-08 PE PE2006000963A patent/PE20070405A1/es not_active Application Discontinuation
- 2006-08-08 ES ES10172674T patent/ES2401128T3/es active Active
- 2006-08-08 CA CA002626723A patent/CA2626723A1/en not_active Abandoned
- 2006-08-08 PL PL06763016T patent/PL1912991T3/pl unknown
- 2006-08-08 EP EP06763016A patent/EP1912991B1/en not_active Not-in-force
- 2006-08-08 AU AU2006278215A patent/AU2006278215A1/en not_active Abandoned
- 2006-08-08 CA CA002618963A patent/CA2618963A1/en not_active Abandoned
- 2006-08-08 AT AT06763016T patent/ATE487719T1/de active
- 2006-08-08 WO PCT/EP2006/007869 patent/WO2007017262A1/en not_active Ceased
- 2006-08-08 BR BRPI0614270-2A patent/BRPI0614270A2/pt not_active IP Right Cessation
- 2006-08-08 DE DE602006018151T patent/DE602006018151D1/de active Active
- 2006-08-08 NZ NZ565494A patent/NZ565494A/en not_active IP Right Cessation
- 2006-08-08 MX MX2008001929A patent/MX2008001929A/es not_active Application Discontinuation
- 2006-08-08 AR ARP060103459A patent/AR055369A1/es unknown
- 2006-08-08 WO PCT/EP2006/007865 patent/WO2007017261A1/en not_active Ceased
- 2006-08-08 EA EA200800564A patent/EA200800564A1/ru unknown
- 2006-08-08 TW TW095128952A patent/TW200800217A/zh unknown
- 2006-08-08 EP EP10172674A patent/EP2272848B1/en active Active
- 2006-08-08 US US12/063,432 patent/US20100179128A1/en not_active Abandoned
- 2006-08-08 DK DK06763016.0T patent/DK1912991T3/da active
- 2006-08-08 US US12/063,434 patent/US8143264B2/en not_active Expired - Fee Related
- 2006-08-08 SI SI200630916T patent/SI1912991T1/sl unknown
-
2008
- 2008-01-28 IL IL189083A patent/IL189083A0/en unknown
- 2008-01-28 IL IL189081A patent/IL189081A0/en unknown
- 2008-02-08 MA MA30628A patent/MA29692B1/fr unknown
- 2008-02-08 MA MA30629A patent/MA29693B1/fr unknown
- 2008-02-21 CR CR9749A patent/CR9749A/es not_active Application Discontinuation
- 2008-02-21 CR CR9748A patent/CR9748A/es not_active Application Discontinuation
- 2008-03-07 NO NO20081211A patent/NO20081211L/no not_active Application Discontinuation
- 2008-03-07 NO NO20081212A patent/NO20081212L/no not_active Application Discontinuation
-
2011
- 2011-01-12 CY CY20111100033T patent/CY1111757T1/el unknown
- 2011-04-18 US US13/088,962 patent/US20110257205A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070405A1 (es) | Compuestos derivados de xantina como agonistas del receptor de acido nicotinico hm74a | |
| AU2010338011B2 (en) | Novel pyrimidine compounds as mTOR and P13K inhibitors | |
| ES2434337T3 (es) | Derivados de azabiciclo[3.1.0]hexilo como moduladores de los receptores D3 de la dopamina | |
| RU2384576C2 (ru) | Сульфонил-замещенные бициклические соединения в качестве модуляторов ppar | |
| PE20061442A1 (es) | Heterociclicos como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia | |
| PE20060599A1 (es) | DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1 | |
| PE20110944A1 (es) | DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINA COMO INHIBIDORES PDE1 | |
| PE20141203A1 (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| PE20081345A1 (es) | Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico | |
| PE20110387A1 (es) | Aminotriazolo-piridinas como inhibidores de cinasa | |
| PE20061353A1 (es) | Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa | |
| JP2006522812A5 (enExample) | ||
| PE20040189A1 (es) | Pirimidina y piridina biciclicos como inhibidores de p38 quinasa | |
| PE20091068A1 (es) | Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor | |
| US20210269427A1 (en) | Process For Preparing Aminopyrimidine Derivatives | |
| ES2685070T3 (es) | Compuesto bicíclico que contiene azufre | |
| JP6403751B2 (ja) | ５−チアゾールカルボキサミン誘導体及びｂｔｋ阻害剤としてのその使用 | |
| PE20081735A1 (es) | Derivados de 1-oxa-3[4,5]decan-2-ona en el tratamiento de trastornos alimenticios | |
| WO2011152485A1 (ja) | 新規４，５－縮環ピリミジン誘導体 | |
| PE20051159A1 (es) | Derivados de heteroarilaminopirazol como estimulantes de la produccion de insulina | |
| PE20020603A1 (es) | Derivados de pirimidina como antagonista del receptor del neuropeptido y (npy) | |
| RU2717830C2 (ru) | Способ получения азотсодержащего гетероциклического соединения и его промежуточного соединения | |
| PE20090629A1 (es) | Pirazinas y piperidinas piperazinil sustituidas como antagonistas del receptor 5-ht7 | |
| EP2501233B1 (en) | Quinazoline compounds | |
| PE20061351A1 (es) | COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |